Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
149 results about "Situ breast cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ductal carcinoma in situ (DCIS) is non-invasive breast cancer. Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues (including breast tissue) that cover or line the internal organs, and in situ means "in its original place.".
Intelligent bra for early detection of breast cancer
InactiveCN104223385AChange the prevention modelSave livesBrassieresDiagnostic recording/measuringWireless transmissionMedicine
Owner:NANKAI UNIV
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
ActiveUS20110150868A1Reduce PTEN tyrosine phosphoryulationEffectively inhibited Src phosphorylationSugar derivativesMicrobiological testing/measurementCancer researchTrastuzumab
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer
InactiveCN107267606ALarge amount of informationComprehensive direct accessMicrobiological testing/measurementDNA/RNA fragmentationHigh homologyLung cancer
The invention discloses lncRNA and application thereof as a detection marker or a prognosis recurrence marker for breast cancer combined with lung cancer. The lncRNA is at least one of the following nucleic acid molecules: (1) nucleic acid molecules with cDNA sequences as shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3; and (2) nucleic acid molecules with 90% and higher homology with the nucleic acid molecules with the cDNA sequences as shown in the SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3. According to the lncRNA and application thereof, a group of lncRNAs are screened out as the molecular markers for the breast cancer combined with lung cancer, associated primers are optimized for preparing primer probe chips, and the lncRNA has the advantages of low detection cost, high sensitivity and the like; and the lncRNA and application thereof take the breast cancer combined with lung cancer, such combined cancer, as an example, and take the lead in filling up the blank in research of the combined biological marker lncRNA in China. The lncRNA and application thereof adopt a group of lncRNAs as associated biological markers for combined cancer, and can effectively improve the clinical diagnosis and prognosis evaluation of the combined cancer for instructing clinical treatment.
Owner:ZHEJIANG SCI-TECH UNIV
Reagent kit for quantitatively assessing long-term recurrence risks of breast cancer
InactiveCN102586410AEasy to operateTest results are stableMicrobiological testing/measurementFluorescence/phosphorescenceGenomicsBreast cancer metastasis
The invention relates to the functional genomic and gene expression detection technology and the analysis technology, and discloses a reagent kit for quantitatively assessing long-term recurrence risks of breast cancer. Particularly, a type of genes capable of being used for breast cancer metastasis and prognostic molecular classification is screened within a human functional genome expression profile range, the detection technology is created, and the reagent kit is prepared and applied to breast cancer metastasis and prognostic assessment for a patient. The reagent kit for quantitatively assessing long-term recurrence risks of breast cancer comprises 21 pairs of primers, 21 specific taqman fluorescent probes, 10XRT-PCR (reverse transcription-polymerase chain reaction) buffer solution, 2.5mM of dNTP (diethyl-nitrophenyl thiophosphate) mixed liquor, reverse transcriptase, DNA (deoxyribose nucleic acid) polymerase, 10XPCR buffer solution and RNA (ribonucleic acid) enzyme inhibitor. The reverse transcription PCR technology is combined with the taqman fluorescent quantitative PCR technology, reverse transcription primers, real-time PCR primers and the taqman fluorescent probes are self-designed and optimized, reverse transcription PCR reagent and taqman fluorescent quantitative PCR reagent are integrated to prepare the detection reagent kit, operation is simple and fast, detection results are more stable, and detection cost is lower.
Owner:苏州科贝生物技术有限公司
Breast cancer related SNP marker
ActiveCN106399304AEasy diagnosisMicrobiological testing/measurementDNA/RNA fragmentationNucleotideBiologic marker
The invention discloses a breast cancer related biomarker. The biomarker comprises an SNP site of which base in the position 8187 from the 5' end of the nucleotide sequence of gene C12orf45 is G, wherein the site is C12orf45:NM_152318:exon4:c.C368G. In the invention, the application prospect of SNP in breast cancer assisted diagnosis is studied, the influence of SNP on the breast cancer progress is elaborated, and the diagnosis value thereof is revealed. Therefore, through the development and application of the SNP biomarker and diagnosis kit, the diagnosis of breast cancer is more convenient and easier to implement, a foundation is laid for the quick and accurate control of the patient condition by clinical doctors and for the evaluation of clinical treatment effect, and the discovery of a novel small-molecule drug target with potential treatment value is facilitated.
Owner:SHENZHEN SHUANGKE BIOTECH CO LTD
Compositions and Methods for Characterizing Breast Cancer
InactiveUS20130059903A1Increase estrogen receptor expressionImprove the level ofOrganic active ingredientsMicrobiological testing/measurementSub populationsCD44
The invention provides compositions and methods for characterizing breast cancer stem In particular, the invention provides for the identification of cells expressing Twist and CD44 that express little or virtually undetectable levels of CD24 (i.e. a Twist+ / CD44+ / CD24− / low cell sub-population). The presence of such cells in a breast cancer specimen identifies the breast cancer as having increased metastic potential. Such cancers are identified as requiring aggressive therapies. Accordingly, the invention provides biomarkers suitable for identifying, diagnosing, and monitoring treatment of a subject with breast cancer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Method and equipment for image-guided stereotactic radiosurgery of breast cancer
Owner:XCISION MEDICAL SYST +1
Method and device for positioning patients with breast cancer in prone position for imaging and radiotherapy
ActiveUS20110047702A1Facilitate easy sliding motionEasy and efficientSofasPatient positioning for diagnosticsLocking mechanismProne position
A method and device for accurately easily and accurately positioning patients with breast cancer in the prone position for imaging and radiotherapy is disclosed. The device is a couch or support structure with a double-layer structure that allows relative planar motion between the two layers. To easily slide the top layer, an array of ball transfer units is embedded on the upper side of the bottom layer while the under side of the top layer has a corresponding array of bearing plates to prevent the ball transfer units from grinding into the top layer. A locking mechanism is specially designed to interlock the two layers safely when a knob handle is tightened. A frame of bars is attached to the bottom layer to constrain translation of the top layer. Each layer has two openings for the through insertion of breasts. When a patient lies in the prone position, the breast to be treated is pendent through the couch, and the untreated breast may be blocked from radiation exposure by a removable opening cover.
Owner:XCISION MEDICAL SYST
Application of gene marker in diagnosis and treatment of breast cancer
The invention discloses an application of a gene marker in diagnosis and treatment of breast cancer. The gene is LINC02544, the invention firstly discovers that expression of LINC02544 in a breast cancer patient is obviously up-regulated, and verification is further carried out through QPCR, so that LINC02544 can be applied to diagnosis of the breast cancer as a biomarker. The invention also discloses that proliferation of breast cancer cells can be effectively inhibited and migration and attack rates of the breast cancer cells can be reduced by reducing expression of LINC02544, so that LINC02544 can be applied to treatment of the breast cancer and shift thereof as a drug target.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
InactiveUS20160060316A1Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence
Owner:CEDARS SINAI MEDICAL CENT
Method for treating breast cancer and ovarian cancer
The present invention relates to a method for the prevention or treatment of certain breast cancers or ovarian cancer comprising administering to a patient in need thereof of a therapeutically effective amount of a 17,20-lyase inhibitor, wherein the breast cancer or ovarian cancer is estrogen receptor (ER) negative.
Owner:TAKEDA PHARMA CO LTD
Breast cancer related gene znfn3a1
InactiveUS20090142344A1Inhibits and enhances expression and activityRelieve symptomsOrganic active ingredientsCompound screeningBreast cancer metastasisNormal cell
Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.
Owner:ONCOTHERAPY SCI INC
Probe for detecting circulating tumor DNA (Deoxyribonucleic Acid) of human breast cancer and application of probe
InactiveCN105950739AStrong specificityHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationDiseaseIndividualized treatment
The invention discloses a probe for detecting a circulating tumor DNA (Deoxyribonucleic Acid) of a human breast cancer and application of the probe, belonging to the field of diagnosis and prevention of diseases. The invention designs a breast cancer selector which consists of DNA segments in mutation regions of related genes of the breast cancer. The circulating tumor DNA (ctDNA) of a breast cancer patient is subjected to liquid-phase hybridization capture by using the probe designed by the selector; after high-throughput sequencing, specific cancer gene variation of a patient is found, and a tumor load is monitored. Compared with a conventional detection means, the probe and the application thereof disclosed by the invention have the characteristics of no invasiveness, high throughout, good sensitivity and specificity, and the like; the probe and the application thereof can be used for better screening and early-stage diagnosis of the human breast cancer and are applied to individualized treatment of cancer.
Owner:HARBIN MEDICAL UNIVERSITY
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
ActiveUS8658370B2Improve expression levelLower Level RequirementsOrganic active ingredientsSugar derivativesMicroRNAOncology
Owner:THE OHIO STATE UNIV RES FOUND
Metabolomic profiling of prostate cancer
The present invention relates to cancer markers. In particular, the present invention provides metabolites and panels of metabolites that are differentially present in cancer (e.g., prostate or breast cancer).
Owner:RGT UNIV OF MICHIGAN
Methods for treating breast cancer
InactiveUS20120202801A1Prevent proliferationControl growthBiocidePharmaceutical non-active ingredientsBlood vesselEndothelial Growth Factors
Methods for treating breast cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
Owner:PTC THERAPEUTICS INC
Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
InactiveUS9850293B2Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Owner:CEDARS SINAI MEDICAL CENT
Biomarkers for assessing breast cancer
The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and / or diagnosing breast cancer, the metabolic biomarker set comprising at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Further, the invention relates to a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity. Further, the invention relates to a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, the present invention relates to a method for assessing breast cancer, which comprises obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and / or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.
Owner:METABOLOMYCS INC
Novel biomarker for the prognosis of breast cancer
InactiveUS20110097732A1Improved prognosisSugar derivativesImmunoglobulins against animals/humansEarly breast cancerOncology
The present invention relates to methods of determining the predilection for survival for an individual having breast cancer comprising: obtaining a breast tissue sample from said individual, measuring the amount of Wrap53 in the nucleus of cells in said breast tissue sample, and / or measuring the amount of Wrap53 in the cytoplasm of cells in said breast tissue sample, and wherein both the nuclear levels, the cytoplasmic levels and / or the ratio between the nuclear and cytoplasmic levels of Wrap53 may be used alone or in combination in breast cancer prognosis. The invention furthermore relates to antibodies and kits relating to Wrap53.
Owner:MEDINNOVA AS
Multi-detection kit for breast cancer 21 gene
PendingCN110129435AExtend the life cycleReduce contributionMicrobiological testing/measurementDNA/RNA fragmentationGynecologyMedical expenses
The invention belongs to the field of biomedicine, relates to a tumor detection kit, and in particular, relates to a detection kit for risk evaluation of breast cancer recurrence. The invention relates to a multi-detection kit for a breast cancer 21 gene; according to the multi-detection kit for the breast cancer 21 gene, provided is a method for multiple detection of the breast cancer 21 gene; the method has the advantages of small used sample size, fast speed, low cost and the like, and is used for serving the majority of breast cancer patients; by early diagnosis and early treatment, required contribution is made for prolonging the life cycle of patients with breast cancer and reducing unnecessary medical expenses.
Owner:深圳塔歌生物技术有限公司
Application of TLCD1 to diagnosis, prognosis and treatment of BC (breast cancer) metastasis
ActiveCN108841965AInhibit transferInhibit migrationMicrobiological testing/measurementAntineoplastic agentsBreast cancer metastasisIn vivo experiment
The invention discloses an application of TLCD1 to diagnosis, prognosis and treatment of BC (breast cancer) metastasis. High expression of TLCD1 in tissue and cells with BC bone metastasis is discovered, which predicts shorter survival time without bone metastasis, and in-vitro and in-vivo experiments prove that down-regulated expression of the gene TLCD1 can inhibit BC migration and invasion, sothat BC bone metastasis is inhibited; based on the discoveries, a reagent for detecting TLCD1 gene expression level is provided to be used for preparing a kit for detecting whether BC metastasis occurs and / or a prognosis kit for predicting BC metastasis tendency; a TLCD1 inhibitory reagent is applied to preparation of drugs for preventing and / or treating BC metastasis, and a new idea is provided for diagnosis, prognosis and treatment of BC metastasis.
Owner:江门市中心医院
Urine protein marker of breast cancer and applications thereof in diagnosis and prognosis
The invention relates to a urine protein marker of breast cancer and applications thereof in diagnosis and prognosis. Specifically, the invention relates to applications of the urine protein marker of breast cancer in early diagnosis and disease monitoring of human breast cancer. The urine protein marker comprises beta-2 microglobulin, alpha-1-acid glycoprotein 1, programmed cell death 6 interacting protein, haptoglobin related protein, addiment C4-A, apolipoprotein A-IV, calcium binding protein, HLA-I histocompatibility antigen, A-3 alpha chain, pancreatic stone protein 1 alpha, blood coagulation factor XII, collectin 12, galectin-3 binding protein, vitamin D binding protein, and the like.
Owner:BEIJING NORMAL UNIVERSITY
Biomarker combination and kit for predicting breast cancer and use method
ActiveCN106636430AHigh detection sensitivityImprove noise immunityMicrobiological testing/measurementDNA/RNA fragmentationBiologyTarget gene
The invention provides a biomarker combination and a kit for predicting breast cancer. Primer design genes are chosen from four types of telomere genes with the most obvious methylation rate difference in breast cancer tissues and normal tissues. According to the promoter regions and coding regions of the four types of telomere genes, methylation primers and qPCR (Quantitative Polymerase Chain Reaction) primers of a target gene are respectively designed, and thereby a methylation primer combination and a qPCR primer combination are formed. Since the biomarker combination provided by the invention is designed according to the telomere genes with the most obvious methylation rate difference in the breast cancer tissues and the normal tissues, when whether a sample is breast cancer is assayed, the biomarker combination can specifically capture and amplify specific DNA fragments in the assayed sample, so that the sensitivity of assay is increased, and the biomarker combination has good noise immunity, flexibility and accuracy, and can be used in the early prediction of the breast cancer, the evaluation and assay of medicines for treatment and the detection of prognosis recurrence. The method for predicting the breast cancer provided by the invention has the advantages of quickness in operation, simplicity, convenience and good feasibility and prediction effect.
Owner:HUNAN SHENGWEI GENE TECH
Cancer biomarker, diagnostic methods, and assay reagents
This disclosure describes APOBEC3B as a biomarker for certain cancers such as, for example, breast cancer. This disclosure therefore describes methods for detecting APOBEC3B in a biological sample. The methods generally include measuring expression of APOBEC3B in a biological sample obtained from a patient and identifying the patient as having or at risk for having cancer if the measured expression of APOBEC3B is greater than a predetermined reference level of expression. This disclosure also describes isolated polynucleotides that may be used as reagents in methods for detecting and / or measuring APOBEC3B expression.
Owner:RGT UNIV OF MINNESOTA
Oligonucleotide targeting SNHG17 for treating breast cancer
ActiveCN110029107ARegulation of proliferationOrganic active ingredientsAntineoplastic agentsCancer cellEarly breast cancer
The invention provides an oligonucleotide targeting SNHG17 for treating breast cancer. The oligonucleotide comprises at least one of an antisense oligonucleotide and small interfering RNA, wherein thesequence of the antisense oligonucleotide is as shown in SEQ ID NO.1, and the sequence of the small interfering RNA is as shown in SEQ ID NO.2-4. The oligonucleotide can regulate and control the proliferation, metastasis and invasion capability of triple-negative breast cancer cells by targeting and silencing SNHG17 gene or down-regulating the expression of the SNHG17 gene in the triple-negativebreast cancer cells, and finally improve or treat triple-negative breast cancer.
Owner:SHENZHEN PEOPLES HOSPITAL
Tetrasubstituted alkene compounds and their use for the treatment of breast cancer
Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and / or the subject in need of treatment may express a mutantER-alpha protein.
Owner:EISIA R&D MANAGEMENT CO LTD
Use of pkc-zeta as a breast cancer tumorigenic biomarker as well as a target for treatment of breast cancer
InactiveUS20120171219A1Organic active ingredientsMicrobiological testing/measurementDiagnostic biomarkerOncology
The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.
Owner:UNIV OF SOUTH FLORIDA +1
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
InactiveUS7504222B2Improve expression levelReduced expression levelMicrobiological testing/measurementBiological testingEarly breast cancerOncology
The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
Owner:MILLENNIUM PHARMA INC +1
Breast cancer marker
The invention relates to the field of biomedicine detection, and provides a breast cancer marker which comprises at least one of glycoproteins such as serum transferrin with end N-acetylglucosamine sugar, plasma protease C1 inhibiting factors with end N-acetylglucosamine sugar and serine protease inhibitors B4 with end N-acetylglucosamine sugar. The quantity of any one, two or all of the glycoproteins in samples to be detected is detected, the breast cancer marker can judge or help to judge occurrence and / or development of breast cancers, and single or any combination of the glycoproteins canserve as markers for screening or auxiliary screening diagnosis of the breast cancers.
Owner:GUANGDONG MEDICAL UNIV
Reagent for prognosis of breast cancer
ActiveCN105586390AEffectively guide clinical treatmentGuide clinical treatmentMicrobiological testing/measurementLow risk groupLower risk
The invention discloses a kit for prognosis and postoperative treatment response prediction of breast cancer. Five miRNAs (miR-205, miR-320a, miR-665, miR-188-5p and miR-198), which are obviously related to the survival prognosis of patients, are discovered by the inventor, wherein two of the miRNAs are protective and the other three miRNAs are dangerous. By virtue of the five miRNAs molecular tags, the patients are classified into patients of high risk and patients of low risk; and overall survivals of the two groups are compared based on survival analysis, discovering that a significant difference exists between the overall survivals of the high-risk group and the low-risk group (p=0.001). The reagent is effective for guiding the clinical treatment of the breast cancer and is capable of conducting appropriate adjuvant therapy on the patients of high risk in prognosis, so that the survival quality of the patients is improved; and meanwhile, unnecessary treatment on the patients of low risk can be avoided.
Owner:王辉云
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap